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1. Introduction 
Tuberculosis (TB) – an infectious airborne disease –is a re-emerging major global health 
problem. Each year, there are around nine million new cases of TB, and close to two million 
deaths among 14 million persons with active clinical disease. All countries are affected, but 
85% of cases occur in Africa (30%) and Asia (55%), of which India and China alone represent 
35% (World Health Organization, 2011).  
Control and cure of tuberculosis has become a very serious problem in recent years because 
of its association with the Acquired Immune Deficiency Syndrome (AIDS) of the Human 
Immunodeficiency Virus (HIV) infection and its increasing resistance to generally used 
antituberculosis drugs (DOTS) (Ferreira Gonçalves, M. J.; Ponce de Leon, A. C. & Fernandez 
Penna, M. L., 2009).  
The HIV epidemic has led to an increase in the incidence of tuberculosis globally, with an 
important increase in the mortality rate. 
Despite this, TB is in most instances, a curable disease with 85% to 90% of people with 
newly diagnosed drug-susceptible TB cured in six months using combinations of first-line 
drugs (Nunn, P.; Williams, B.; Floyd, K.; Dye, C.; Elzinga, G. & Raviglione, M., 2005). 
Treatment of multidrug-resistant TB (MDR-TB), of which there are around 0.5 million cases 
each year, is more exigent and the use of newer therapies is required. Cure rates for MDR-
TB are lower, typically ranging from around 50% to 70% (World Health Organization, 2011). 
Extensively drug-resistant TB has been reported in 45 countries, including countries with 
limited resources and a high TB burden (Mitnick, C. D.; Shin, S. S.; Seung, K. J.; et. al., 2008). 
When tuberculosis patients (TBP) are co-infected with HIV, have drug-resistant or relapsed 
TB, the commonly indicated drugs are less effectives. It takes between 12-24 months to cure 
such patients. In these cases second line drugs are required. This involves a significant 
increase in the cost of therapy, particularly important in poor countries (Arjanova, O. V.; 
Prihoda, N. D.; Yurchenko, L. V.; Sokolenko, N. I.; Frolov, V. M.; Tarakanovskaya, M. G.; 
Batdelger, D.; Jirathitikal, V. & Bourinbaiar, A. S., 2011).  
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Considerable labors are aimed at finding new drugs and vaccines against TB and several 
immune-based interventions have been proposed as adjunct immunotherapy to 
conventional treatment. 
Thus, TB is considered a re-emerging global public disease, particularly in developing 
countries, where its incidence has reached alarming proportions. BCG, the only vaccine 
available for prevention in humans has been inefficient when tested in several field trials. It 
is therefore an urgent need for new vaccines against tuberculosis to be developed. A better 
understanding of the immune response induced during infection with Mycobacyterium 
tuberculosis (M. tuberculosis, Mtb) could help in a relatively short time to obtain the desired 
vaccine against this organism (García, M. A.; Sarmiento, M. E. & Acosta, A., 2009).  
TB accounted for one in four deaths among HIV-positive people. Coinfection with HIV 
leads to difficulties in both the diagnosis and treatment of tuberculosis. Because of the poor 
performance of sputum smear microscopy in HIV-infected patients, more sensitive tests—
such as liquid culture systems, nucleic acid amplification assays, and detection of 
mycobacterial products in various body fluids—are being investigated. The treatment of 
coinfected patients requires a combined therapy of antituberculosis and antiretroviral drugs 
administered concomitantly. Difficulties include pill burden and patient conformity, drug 
interactions, extending beyond the toxic effects, and immune reconstitution syndrome. Both 
multidrug-resistant and extensively drug-resistant tuberculosis can spread rapidly among 
an immunocompromised population, with resulting high mortality rates. Current guidelines 
recommend starting antiretroviral treatment within a few weeks of antituberculosis therapy 
for patients with CD4 cell counts <350 cells/µL. However, important problems concerning 
the drug regimens and timing of antiretroviral therapy still remain unresolved. Ongoing 
trials may answer many of these questions (Swaminathan. S.; Padmapriyadarsini, C. &, 
Narendran, G., 2010).  
The risk of developing tuberculosis is estimated to be between 20-37 times greater in people 
living with HIV than among those without HIV infection. In 2009 there were 9.4 million new 
cases of TB, of which 1.2 (13%) million were among people living with HIV and of the 1.7 
million people who died from TB 400,000 (24%) were living with HIV. With 13% of new TB 
cases and 24% of TB deaths being HIV associated, TB is a leading cause of morbidity and 
mortality among people living with HIV and as such TB remains a serious health risk for 
people living with HIV. The AIDS and Rights Alliance for Southern Africa (ARASA), in 
collaboration with WHO hosted a workshop to develop an advocacy toolkit on the Three I's 
for HIV/TB based on WHO policy for healthcare workers, HIV/TB advocates (World Health 
Orgamization, 2011). Several factors including previous therapeutic failure, duration of 
antiretroviral therapy, low CD4+ T-cell count at the initiation of HAART, severe 
manifestations of disease, low adherence to HAART, and previous treatment interruption 
are contributory of defective immune reconstitution. It was not definitively demonstrated 
that age, viral strain/clade, or host genetic factors play a role in these different responses to 
HAART (Aiuti, F. & Mezzaroma, I., 2006). 
The roles of different T-cell subsets which participate in the protector mechanisms against 
M. tuberculosis, thymic function, and cytokines involved in immune response against the 
bacilli have been investigated. The increased T-cell activation or apoptosis has been 
associated with a deficiency of effective immunologic response. The continuous virologic 
www.intechopen.com
 
Therapy for Tuberculosis: M. vaccae Inclusion into Routine Treatment 
 
475 
replication in lymphoid tissues, regardless of the undetectable plasma viral load, has been 
proposed as the fundamental mechanism of cellular activation. This incoherent response 
probably can be associated with other procedures. Insufficient CD4+ T-cell repopulation of 
lymphoid tissues may be due to a thymus failure or a defect in bone marrow function. 
Permanent infection, the toxic effect of antiviral drugs on T- and B-cell precursors, the 
severity of disease, and the low number of CD4+ T-cells before HAART could also prime for 
thymus exhaustion and deficient T-cell renewal. Finally, an imbalance in the production of 
cytokines such as TNF-, IL-2 and IL-7 may also be crucial for the induction of immune 
system failure. In patients in which CD4+ T-cells are not increased by HAART, therapeutic 
tactics aimed at increasing these cells and reducing the risk of infections are needed. IL-2 
and/or other cytokines may be of benefit in this scene. Some antiviral drugs may be better 
than others in immunologic reconstitution. Protease inhibitors may have additional, 
independent positive effects on the immune system.  
There may be little justification for using immunosuppressive agents such as cyclosporine or 
hydroxyurea in this subgroup of immunologic non responder patients, as these molecules 
may increase T-cell decline and/or favor susceptibility to infections  
Different mechanisms are involved in the control of the tuberculosis dissemination such as 
granuloma. 
Granulomas, the hallmark of the host response to mycobacterial infection, represent a 
strategy to physically contain infections that cannot otherwise be eradicated by host 
defenses. The successive recruitment of cells to the site of M. tuberculosis infection forms a 
physical barrier to mycobacterial propagation and creates a hostile microenvironment in 
which oxygen tension, pH, and micronutrient supply may all be reduced. In this 
environment, mycobacteria go through profound alterations in metabolism, biosynthesis, 
and replication. 
This adaptation creates the basis of clinical latency in tuberculosis. Although these 
sequestered, semidormant bacilli have been much investigated, their paucity makes direct 
studies in vivo problematic, and multiple researches on this question have been performed 
such as in vitro oxygen deprivation or intracellular growth in macrophages (Wallis, R. S., 
2005). 
M. tuberculosis is an atypical member of its genus (Stanford, J. L.; Bahr, G. M.; Rook, G. A. 
W.; Shaaban, M. A.; Chugh, T.D.; Gabriel, M.; Al-Shimali, B.; Siddiqui, Z.; Ghardanis, F.; 
Shahin, A. & Behbehani, K., 1990). Apparently the capacity of M. tuberculosis to cause illness 
is due not only to the severity of the damage it causes to the host tissue but also to its 
aptitude to alter the immune response, to one that is inappropriate. It is evident that new 
alternative and improved treatment options are needed. In consequence, more efficient 
resources were considered crucial to improve the employed chemotherapy. Significant 
efforts have been directed at finding new drugs and vaccines against TB. (Small, P. M., 
2009). Thus, the immunomodulatory effects of a heat killed Mycobacterium vaccae (M. vaccae, 
Mv) preparation have been investigated by Stanford, J. et. al. during the 1970´s.  
It has been stated that the variation of disease expressions and severity was entirely inherent 
in the host and his surroundings, disease depending on human genetic control of the 
immunological response in interaction with environmental factors rather than to bacterial 
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features. In the environment a free-living mycobacterium, the potentially beneficial M. 
vaccae was recognized as an important source for influencing the human immune response 
(Stanford, J.L. & Paul, R. C., 1973; Stanford, J. L. & Rook, G. A.W., 1983). 
Several studies using an optional new therapy, which involved the addition of a preparation 
of inactivated M. vaccae, were carried out over the last twenty-five years with successful 
results. In those investigations it has been shown that the killed bacterium or its components 
are enhancers of the immune responses in opposition to different infectious agents. A 
number of pre-clinical studies of tuberculosis, bronchospasm, Trypanosoma cruzi infection, 
Leishmaniasis, autoimmune conditions and cancer have been also carried out in mice, 
demonstrating protection induced by this treatment. (Hernandez-Pando, R.; Pavon, L.; 
Arriaga, K.; Orozco, H.; Madrid-Marina, V. & Rook, G., 1997; Zuany-Amorim, C.; Sawicka, 
E.; Manlius, C.; Le Moine, A.; Brunet, L. R.; Kemeny, D. M.; Bowen, G.; Rook, G. & Walker, 
C., 2002; Valian, H. K.; Kenedy, L.K.A.; Rostami, M.N.; Mohammadi, A. M. & Khamesipour, 
A., 2008).  
Some promising results have been reported of its immune stimulative action against M. 
tuberculosis infection, tumors such as melanoma and adenocarcinoma, and pollen-induced 
asthma (Hopkin, J.M.; Shaldon, S.; Ferry, B.; Coull, P. P. A.; Enomoto, T.; Yamashita, T.; 
Kurimoto, F.; Stanford, J.; Shirakawa, T. & Rook, G. A. W., 1998; Maraveyas, A.; Baban, B.; 
Kennard, D.; Rook, G. A.; Westby, M.; Grange, J. M.; Lydyard, P.; Stanford, J. L.; Jones, M.; 
Selby, P. & Dalgleish, A. G., 1999; Stanford, J. L.; Stanford, C. A.; O’Brien, M.; Grange, J. M., 
2008; Hrouda, D.; Souberbielle, B. E.; Kayaga, J.; Corbishley, C. M.; Kirby, R. S. & Dalgleish, 
G., 1998).  
2. Clinical trials of adjunctive immunotherapy  
The concept of immunotherapy in tuberculosis is not new and many immune based 
interventions have been investigated as adjuncts to convenional chemotherapy. It is evident 
that the modulation of immune reactivity can be of great therapeutic value. 
IFN- As IFN- is central to antimycobacterial host defenses; it has been used in several 
clinical trials of adjunctive immunotherapy. In mice, IFN-enhances the mycobactericidal 
capacity of macrophages by increasing the production of reactive nitrogen intermediates, 
such as nitric oxide. Condos et al. reported in 1997 the first study of therapeutic IFN- in 
patients with tuberculosis without evident defects on IFN- production or responsiveness. 
In this investigation 500 g of IFN- was administered 3 times per week by aerosol to 5 
patients with MDR tuberculosis together with their previous therapy. The study found that 
sputum smear results became negative and the number of colony-forming units (CFU) 
tended to fall. Three similar successive studies performed by other investigators showed 
that differed in IFN- type, dose, and route of administration were not successful in 
inducing any hopeful results. The only randomized, placebo-controlled, multicenter trial of 
inhaled adjunctive IFN- for MDR tuberculosis was done by InterMune in 2000, and the trial 
was stopped because of a lack of efficacy and the data obtained have never been published. 
Subsequent investigations have indicated that IFN-–induced genes, such as IP-10 and 
iNOS, are already upregulated in the lung in patients with tuberculosis and that therapeutic 
aerosol IFN- has a relatively minor additional effect. These findings indicate that the fairly 
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small mycobactericidal capacity of lung macrophages cannot effectively be increased by 
therapeutic IFN-Wallis, R. S., 2005) 
IL-2 Considering that IL-2 is able to induce T cell replication and is essential for cellular 
immune function and granuloma formation, a small, unblinded study of 2 low-dose IL-2 
regimens (daily or in 5-day “pulses”) in patients with MDR tuberculosis demonstrated that 
the daily treatment produce a decrease of sputum counts of acid-fast bacilli (Johnson, B. J.; 
Bekker, L. G.; Rickman, R.; Brown, S.; Lesser, M.; Ress, S.; Willcox, P.; Steyn, L. & Kaplan, G., 
1997; Wallis, R. S., 2005). 
Taking into account this observation, a randomized, double-blind, placebo-controlled study 
of the effect of IL-2 on conversion of sputum culture was conducted by the Case Western 
Reserve University Tuberculosis Research Unit (Cleveland, OH) with 110 Ugandan, HIV-
uninfected patients with drug-susceptible tuberculosis (Johnson, J. L.; Ssekasanvu, E.; 
Okwera, A.; Mayanja, H.; Hirsch, C. S.; Nakibali, J. G.; Drzayich Jankus, D.; Eisenach, K. D.; 
Boom, W. H.; Ellner, J. J. & Mugerwa, R. D., 2003; Wallis, R. S., 2005).  
IL-2 or placebo was administered twice daily for the first month of standard therapy. 
Contrary to expectations, the study found significant delays in clearance of viable M. 
tuberculosis CFU and conversion of sputum culture results in the IL-2 treatment arm. This 
report suggested a possible antagonism during combined chemotherapy and 
immunotherapy for tuberculosis.  
TNF-TNF-, like IFN-, is crucial for host defenses against tuberculosis. TNF- is a potent 
proinflammatory cytokine, expressed by macrophages and T cells, (Wallis, R.S.; Amir 
Tahmasseb, M. & Ellner, J. J., 1990; Black, R. A.; Rauch, C.T.; Kozlosky, C.J.; Peschon, J. J.; 
Slack, J. L.; Wolfson, M. F.; Castner, B.J.; Stocking, K. L.; Reddy, P.; Srinivasan, S.; Nelson, N.; 
Boiani, N.; Schooley, K. A.; Gerhart, M.; Davis, R.; Fitzner, J. N.; Johnson, R. S.; Paxton, R. J.; 
March, C. J. & Cerretti, D. P., 1997; Wallis, R. S., 2005). TNF- stimulates the release of 
inflammatory cytokines, endothelial adhesion molecules, and chemokines, and is considered 
essential for the formation and conservation of granulomas. 
Monocytes express TNF- after phagocytosis of mycobacteria or after stimulation by 
mycobacterial proteins or glycolipids (Wallis, R.S.; Amir Tahmasseb, M. & Ellner, J. J., 1990; 
Wallis, R. S.; Paranjape, R. & Phillips, M., 1993; Valone, S.E.; Rich, E. A.; Wallis, R. S. & 
Ellner, J. J., 1988; Barnes, P. F.; Chatterjee, D.; Abrams, J. S.; Lu, S.; Wang, E.; Yamamura, M.; 
Brennan, P. J. & Modlin, R. L., 1992; Wallis, R. S., 2005). TNF-is produced at the site of 
disease in patients with newly diagnosed tuberculosis (Ribeiro-Rodrigues, R.; Resende Co, 
T.; Johnson, J. L.; Ribeiro, F.; Palaci, M.; Sá, R. T.; Maciel, E. L.; Pereira Lima, F. E.; Dettoni, 
V.; Toossi, Z.; Boom, W. H.; Dietze, R.; Ellner, J. J. & Hirsch, C. S., 2002; Barnes, P. F.; Fong, S. 
J.; Brennan, P. J.; Twomey, P. E.; Mazumder, A. & Modlin, R. L., 1990; Bekker, L. G.; 
Maartens, G.; Steyn, L. & Kaplan, G., 1998; Wallis, R. S., 2005). It have been shown a small 
increase of TNF- level occurs after initiation of antituberculosis therapy (Bekker, L. G.; 
Maartens, G.; Steyn, L. & Kaplan, G., 1998; Wallis, R. S., 2005), possibly attributed to 
microbial constituents that stimulate TNF- production (Wallis, R. S.; Perkins, M.; Phillips, 
M.; Joloba, M.; Demchuk, B.; Namale, A.; Johnson, J. L.; Williams, D.; Wolski, K.; Teixeira, L.; 
Dietze, R.; Mugerwa, R. D.; Eisenach, K. & Ellner, J. J., 1998; Wallis, R. S.; Phillips, M.; 
Johnson, J. L.; Teixeira, L.; Rocha, L. M.; Maciel, E.; Rose, L.; Wells, C.; Palaci, M.; Dietze, R.; 
Eisenach, K. & Ellner, J. J., 2001; Aung, H.; Toossi, Z.; Wisnieski, J. J.; Wallis, R. S.; Culp, L. 
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A.; Phillips, N. B.; Phillips, M.; Averill, L. E.; Daniel, T. M. & Ellner, J. J., 1996; Wallis, R. S., 
2005). Levels subsequently decrease as the bacillary burden is diminished by treatment 
(Ribeiro-Rodrigues, R.; Resende Co, T.; Johnson, J. L.; Ribeiro, F.; Palaci, M.; Sá, R. T.; Maciel, 
E. L.; Pereira Lima, F. E.; Dettoni, V.; Toossi, Z.; Boom, W. H.; Dietze, R.; Ellner, J. J. & 
Hirsch, C. S., 2002; Wallis, R. S., 2005). It was shown in experimental animals that 
neutralization of TNF- interferes with the early recruitment of inflammatory cells to the 
site of M. tuberculosis infection and inhibits granulomas formation (Kindler, V.; Sappino, A. 
P.; Grau, G. E.; Piguet, P. F. & Vassalli, P., 1989; Algood, H. M.; Lin, P. L.; Yankura, D.; Jones, 
A.; Chan, J. & Flynn, J. L., 2004; Wallis, R. S., 2005), and TNF- blockade also reduces the 
microbicidal activity of macrophages and natural killer (NK) cells (Roach, D. R.; Bean, A. G.; 
Demangel, C.; France, M. P.; Briscoe, H. & Britton, W. J., 2002; Hirsch, C. S.; Ellner, J. J., 
Russell, D. G. & Rich, E. A., 1994; Wallis, R. S., 2005). 
The effects of potent immunosuppressive and/or anti-TNF- therapies on microbiologic 
outcomes in tuberculosis have been investigated in two controlled clinical trials. Both were 
conducted with HIV-1–infected patients who had relatively well -preserved tuberculosis 
immune responses (based on the presence of high CD4 cell sum and cavitary lung disease). 
The studies shared a single placebo control arm (for tuberculosis therapy only). Their major 
aim was to examine the role of TNF- in the HIV disease progression due to tuberculosis; as 
such, their main end points were CD4 cell count and plasma HIV RNA load. Nevertheless, 
both studies prospectively accrue clinical and microbiologic data as indicators of safety.  
High-dose methylprednisolone: In a comparative study was reported (Mayanja-Kizza, H.; 
Jones-Lopez, E.; Okwera, A.; Wallis, R. S.; Ellner, J. J.; Mugerwa, R. D.; Whalen, C. C. & 
Uganda-Case Western Research Collaboration, 2005; Wallis, R. S., 2005) in which 189 
subjects received either prednisolone (2.75 mg/kg/day) or placebo during the first month of 
conventional anti-TB therapy. The prednisolone dosage was selected on the basis of a phase 
I study indicating that it reduced the rate of tuberculosis-stimulated TNF- production ex 
vivo by one-half. During the second month, the daily dose was reduced to 0 mg/kg; the 
average subject received a cumulative dose of 16500 mg. Though there is extensive 
experience with the use of corticosteroids to diminish tuberculosis symptoms, no previous 
studies have examined the microbiologic effects of doses of this magnitude. Unexpectedly, 
one-half of prednisolone-treated subjects had conversion of sputum culture results to 
negative after 1 month of treatment, compared with 10% of subjects in the placebo arm 
(P<0.001). This effect was bigger than that observed in the landmark study in which the 
addition of rifampin to a 6-month regimen of streptomycin and isoniazid reduced the 
relapse rate from 29% to 2% and increased the 2-month sputum culture conversion rate from 
49% to 69% (East African-British Medical Research Councils, 1974; Wallis, R. S., 2005). The 
effect of prednisolone therapy was not due to reduced sputum production, which decreased 
similarly during treatment in both study arms. There were no serious opportunistic 
infections. However, prednisolone-treated subjects were more likely to experience other 
early serious adverse events, including edema, hyperglycemia, electrolyte disturbances, and 
severe hypertension. 
Two other prospective, randomized trials of adjunctive corticosteroids administered at 
lower doses have observed similar, albeit smaller, effects on the kinetics of conversion of 
sputum culture results (Bilaceroglu, S.; Perim, K.; Buyuksirin, M. & Celikten, E., 1999; 
Wallis, Horne, N.W., 1960; R. S., 2005), but a third trial found no effect (Tripathy, S.P.; 
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Ramakrishnan, C.V.; Nazareth, O.; Parthasarathy, R.; Santha Devi, T.; Arumainayagam, 
D.C.; Balasubramaniam, R.; Rathasabapathy, S.V. & Manjula Datta, S., 1983; Wallis, R. S., 
2005).  
There have been no reports of deleterious effects of corticosteroids on microbiologic 
outcomes in patients withTB. 
Early studies of immunotherapy for TB were those of Robert Koch who used injections of “old 
tuberculin” during the last 10 years of the 19th century (Koch, R., (a) 1890; Koch, R., (b) 1890). 
In the early 20th century, Charles Stevens developed “Stevens cure” based on a root called 
Umckaloabo from South Africa (Sechehaye, A., 1920), recently shown to have potent anti-
mycobacterial activity (Seidel, V. & Taylor, P. W., 2004; Kim, C. E.; Griffiths, W. J. & Taylor, 
P. W., 2009) and particularly to act as a TNF- antagonist. In 1904 Friedrich Friedmann 
developed a turtle tubercle suspension of live Mycobacterium chelonae, which he later called 
“Anningzochin” which was available until recently from Laves-Arzneimittel GmbH, 
Barbarastr. 14, A-30952, Ronnenberg, Germany (Friedmann, F., 1904; Hart, C. A.; Beeching, 
N. J. & Duerden, B. I., 1996; Rosenau, M. J.& Anderson, J., 1915). Although Friedman 
investigated this mycobacterium species and showed that it was able of confer immunity 
against tuberculosis, he never considered that it might cause a limited tuberculous process. 
In the 1920s and 30s, Henry Spahlinger developed a serum from horses immunized with 
various extracts of tubercle bacilli (Spahlinger, H.; Macassey, L. & Saleeby, C. W., 1934). 
Even though many investigations supported the success of these different preparations in 
the treatment of tuberculosis, until very recently immunotherapy has not contributed 
significantly to its treatment (Sechehaye, A., 1920). 
2.1 Immunomodulatory therapy in tuberculosis  
Two problems confronted the early attempts of immunotherapy for tuberculosis. First, in 
the absence of drugs, the immunotherapy was directed towards the total destruction of the 
tubercle bacillus in the host. Secondly it was then thought that the triggering of immune 
reactivity in tuberculosis was synonymous with protection. The concept of immune 
reactivity in mycobacterial infections embraces both protective immunity and also tissue 
destruction. Distinguishing between them has been a controversial topic for many years 
(Stanford, J. L. & Rook, G. A.W., 1983). During the last decades it was resolved by the 
demonstration of two functional subpopulations of helper T cells - TH1 and TH2 (Flynn, J. 
L. & Ernst, J. D., 2000).  
Immunotherapy, is directed to replace an inadequate immune reaction by an appropriate 
one. The keys to reaching success for immunotherapy arise from the evidence of the 
considerable variation in the efficacy of vaccination with BCG from one country to another. 
This is due to prior contact with environmental mycobacteria, which, depending on species, 
could provide some degree of protection or the antagonistic reaction of tissue necrosis. 
Although the search for new vaccines and immunotherapies should continue, investigation 
of those already available to us is important and is the purpose of our investigations. 
For many years it has been accepted that variation in clinical presentation and severity 
entirely rested in the host and his environment, disease depending on an interaction 
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between human genetic control of the immunological response influenced by environmental 
factors. In the environment are the free-living mycobacteria and it was from amongst them 
that the potentially beneficial M. vaccae and the deleterious M. scrofulaceum were identified 
as important factors influencing the human immune response (Stanford, J. L. & Paul, R. C., 
1973; Stanford, J. L. & Rook, G. A.W., 1983). It is now established that genetic diversity 
within Mtb, expressing significant phenotypic differences between clinical isolates, may also 
be important (Flynn, J. L. & Ernst, J. D., 2000). 
BCG is commonly referred to as a vaccine but its effects are very different from those of 
other vaccines and it is better designated as an immune modulator influencing susceptibility 
to leprosy (Truoc, L. V.; Ly, H. M.; Thuy, N. K.; Trach, D. D.; Stanford, C. A. & Stanford, J. 
L., 2001) and malignant melanoma (Grange, J. M.; Stanford, J. L.; Stanford, C. A. & Kölmel, 
K. F., 2003) as well as tuberculosis. Indeed the concept of a vaccine in its commonly used 
sense against tuberculosis is a difficult one as illustrated by the difficulty in interpreting the 
Tuberculin test. A positive Tuberculin test can signify protection, susceptibility and the 
presence of disease (Stanford, J. L. & Lemma, E., 1983), thus attempting to vaccinate using 
the species-specific, group iv antigens of Mtb (Stanford, J.; Stanford, C.; Stansby, G.; 
Bottasso, O.; Bahr, G. & Grange, J., 2009) is unlikely to be successful. 
3. Immunotherapy with Mycobacterium vaccae in the treatment of respiratory 
disease 
3.1 Mycobacterium vaccae - a part of our environment 
The idea of using a saprophytic mycobacterium that causes no harm, has few side effects 
and is unable to induce adverse reactions in patients, as a potential immunotherapeutic or 
vaccine has only been considered during the last few years. Mycobacterium vaccae (NCTC 
11,659), is a rapidly growing scotocromogenic organism.  
First isolated in Germany from the surroundings of cattle, the potential and the importance 
of the species was first appreciated from field studies in Uganda. A killed suspension of this 
strain was first added to BCG and investigated as a combined vaccine. Later it was 
recognized as an immunotherapeutic agent. Immunotherapy with M. vaccae improves 
immune recognition of common mycobacterial antigens and also regulates immune 
reactions away from necrotic processes. The re-introduction of cellular responsivness to 
common mycobacterial antigens indicates that M. vaccae should induce protective immunity 
and suppress antagonostic responses. Looked at in the opposite way, failure to make a 
response to common mycobacterial antigens is an attribute of diseases that should be 
responsive to treatment with heat-killed M. vaccae. 
3.2 M. vaccae, its adjuvants 
The cell walls of all mycobacteria possess potent adjuvant activity attributed to structural 
lipids and glyco-lipids. 
The actions of these adjuvants vary between species. Thus BCG and most species of 
mycobacteria enhance the type of immune response for which the recipient is already 
primed, whereas M. vaccae and probably a small number of other Actinomycetales enhance 
the most beneficial cellular immune responses. 
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3.3 M. vaccae, its antigens 
M. vaccae possesses the group i antigens shared by all mycobacteria and most other aerobic 
genera of the Actinomycetales. 
Some of these antigens are partially cross-reactive with those expressed by mitochondria, 
when stressed, in animal tissues. 
M. vaccae lacks the groups ii and iii antigens, and the group iv antigens of pathogenic 
mycobacterial species. 
All the information obtained from several studies performed in countries around the 
world, from minor investigations to those made using a placebo control and a properly 
randomized trial, show that increased cure rates in newly diagnosed TB patients receiving 
M. vaccae is only associated with minimal side effects. Studies of immunotherapy with M. 
vaccae in drug-resitant, relapsed and chronic TB Patients have shown that it is also 
favorable under these conditions. The effects are more readily seen when specific 
chemotherapy is difficult to establish or ineffective because of low patient compliance, or 
resistance to multiple drugs. 
Progress was suggested from the early work with irradiation-killed organisms in leprosy to 
the study in London of modulation of tuberculin skin-test responses, and the first 
comparative trials in The Gambia and Kuwait. In these successive investigations the dose of 
109 heat-killed organisms, equivalent to 1 mg wet-weight of bacilli, has been used as a 
standard dose. A series of small trials in Argentina, India, Nigeria, Romania, South Africa, 
Uganda and Vietnam have shown that the method can be effective across wide-ranging 
geographic variability, with South Africa as the only country where almost no effects were 
recorded (Dlugovitzky, D.; Stanford, C. & Stanford, J., 2011).  
Despite this wide geographical efficacy, it is likely that the schedule of treatment with M. 
vaccae should change with different environments. Thus single doses were effective in the 
Gambia, Nigeria, Kuwait, Romania and the UK, but further South in Africa the environment 
may necessitate multiple doses, just as some diseases such as cancer require repeated doses 
to overcome the drive towards Th2 exerted by the tumour. 
Numerous studies have shown that certain patterns of cellular immunity are associated with 
active disease and others are associated with health and recovery from disease. Modulating 
the immune response from the one to the other is now possible with M. vaccae and this 
chapter records its successful achievement (Ottenhoff, T.H.; Verreck, F. A. & Lichtenauer-
Kaligis, E. G., 2002; Dlugovitzky, D.; Torres-Morales, A.; Rateni, L.; Farroni, M.A.; Largacha, 
C.; Molteni, O. & Bottasso, O.A., 1997). 
3.4 Our initial studies on immune response against M. tuberculosis  
The purpose of the early series of studies that we have carried out to investigate the immune 
response of patients with pulmonary tuberculosis has been to make steps towards 
immunotherapy as an effective addition to standard short-course chemotherapy and to 
identify proper in vitro alternative markers of successful treatment for its evaluation. A good 
deal of the immunological work on TB has been done on murine models – animals that have 
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short lives and do not normally suffer from this disease. And in consequence we wanted to 
make use of appropriate methods for and related to human patients. 
Initial studies in our laboratory in Rosario, Argentina, have shown that the changes in 
cellular immune response in pulmonary tuberculosis patients are related to the severity of 
disease and to the administration of tuberculosis chemotherapy. We showed that increased 
levels of IL-8 in the pleural exudates of patients with pulmonary tuberculosis, in comparison 
with those patients with pneumonia-associated pleural effusions, was associated with 
different levels of expression of CD3, CD4, CD19, CD25 and CD68 markers on their cells 
(Dlugovitzky, D.; Rateni, L.; Torres-Morales, A.; Ruiz-Silva, J.; Piñesky, R.; Canosa, B.; 
Molteni, O. & Bottasso, O., 1997; Caruso, A. M.; Serbina, N.; Klein, E.; Triebold, K.; Bloom, B. 
R. & Flynn, J. L., 1999). This data suggested that increased IL-8 levels in pleural effusions 
plays a key role in initiation and maintenance of inflammatory reactions.  
Patients with moderate to severe pulmonary tuberculosis showed a marked and significant 
decrease in their circulating levels of cells bearing these phenotypes when compared with 
those of healthy persons, with patients with pneumonia-associated pleural effusions or with 
patients with mild pulmonary tuberculosis. Differences between the levels of these cell 
markers on pleural and peripheral T-cells from pulmonary tuberculosis patients may be the 
consequence of an incursion of T-lymphocytes from the circulatory system to the pleural 
cavity, probably linked to the presence of chemokines within the pleural fluid including IL-8 
(Fulton, S.A.; Reba, S. M.; Martin, T.D. & Boom, W. H., 2002).  
In other assays in pulmonary tuberculosis, circulating immune complexes and the main 
peripheral blood T-cell subsets were evaluated (Dlugovitzky, D.; Luchesi, S.; Torres-Morales, 
A.; Ruiz-Silva, J.; Canosa, B.; Valentini, E. & Bottasso, O., 1995). This showed that immune 
complex levels in cases with severe disease are significantly higher, and expression of CD4 on 
T lymphocytes significantly lower than in cases of mild disease (Fiorenza, G.; Farroni, M. A.; 
Bogué, C.; Selenscig, D.; Martinel Lamas, D. & Dlugovitzky, D., 2007). Diverse studies of our 
group helped to explain the effective cellular immune response detected in less severe 
tuberculosis cases and simultaneously, the impaired cell-mediated immune response in severe 
cases. Several immune mechanisms within cell-mediated immunity generate a multifaceted 
response involving activated macrophages, T cells, and cytokines directed to manage 
mycobacterial infection. Other cell populations also take part in the immune response against 
mycobacteria and may be important in the development of the disease (Dlugovitzky, D.; 
Torres-Morales, A.; Rateni, L.; Farroni, M.A.; Largacha, C.; Molteni, O. & Bottasso, O.A., 1997; 
Dlugovitzky, D.; Bay, M. L.; Rateni, L.; Urízar, L.; Rondelli, C. F.; Largacha, C.; Farroni, M. A.; 
Molteni, O. & Bottasso, O. A., 1999; Dlugovitzky, D.; Bay, M. L.; Rateni, L.; Fiorenza, G.; Vietti, 
L.; Farroni, M. A. ; Bottasso, O. A., 2000).  
Polymorphonuclear neutrophils (PMN) are the professional phagocytes first at the site of 
bacterial invasion and are able to play a protective role in opposition to M. tuberculosis in the 
early phase of infection controlled by T lymphocytes. Although recruitment of neutrophils 
to bronchoalveolar spaces has been described during active human tuberculosis and 
associated with local chemokine expression, it has not been clarified whether neutrophils 
have direct bactericidal or immunologic functions. In vitro studies suggest that human 
neutrophils are mycobacteriocidal and are activated by soluble mycobacterial antigens 
(Fiorenza, G.; Bottasso, O. A.; Rateni, L.; Farroni, M. A. & Dlugovitzky, D., 2003). 
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Several mechanisms including phagocytosis of bacteria and the subsequent generation of 
reactive oxygen intermediates during oxidative bursts are considered important instruments 
for destruction of mycobacteria (Jones, G. S.; Amirault, H. J. & Andersen, B. R., 1990). 
Several findings demonstrated a significant alteration in PMN functions in pulmonary 
tuberculosis. Production of reactive oxygen intermediates was reduced in severe disease 
and was significantly increased by antituberculosis chemotherapy (Denis, M. J., 1991). 
Recognition of Mtb by phagocytic cells leads to cell activation and production of cytokines, 
which in itself leads to further activation and cytokine production in a complex process of 
regulation and cross-regulation (Denis, M. J., 1991). Thus phagocytic cells are thought to 
contribute to the control of infection through the production of chemokines (Appelberg, R.; 
Castro, A. G.; Gomes, S.; Pedrosa, J. & Silva, M. T., 1995), the induction of granuloma 
formation (Riedel, D. D. & Kaufmann, S. H., 1997) and the transference of their own 
microbicidal molecules to infected macrophages (Ehlers, S., 2003). Levels of circulating 
cytokines correlate significantly with the severity of the disease, antibody concentration and 
the reduction of Th1 activities. We evaluated plasma cytokines of type-1 and type-2 in 
relation to humoral and cell-mediated responses in patients with different amounts of lung 
damage and with different clinical symptoms of tuberculosis. We found that patients with 
pulmonary tuberculosis of different levels of severity have higher serum levels of IFN-, IL-
2, IL-4 and IL-10 when compared with those of healthy controls. Mean titers of IFN-, and 
IL-2, in mild and moderate patients were found to be greater than in those with severe 
disease, whereas moderate and advanced patients showed higher levels of IL-4 in 
comparison with mild cases. Raised levels of interleukin-10 were more prevalent in 
advanced disease, and statistically different from those in patients with mild disease. This 
cytokine pattern would explain the effective cellular immune responses found in patients 
with less severe tuberculosis in comparison with those of patients with advanced disease in 
whom cellular immunity is seriously damaged (Dlugovitzky, D.; Luchesi, S.; Torres-
Morales, A.; Ruiz-Silva, J.; Canosa, B.; Valentini, E. & Bottasso, O., 1995). 
We investigated the relationship between the competence of lymphocytes to proliferate and 
induce cytokine synthesis in vitro, in response to stimulation with antigens, and the amount 
of pulmonary involvement in tuberculosis patients. Higher levels of IFN- compared with 
IL-4 in culture supernatants of Peripheral Blood Monuclear Cells (PBMC) stimulated with 
Mtb antigens were observed in patients with mild tuberculosis (Bay, M. L.; Dlugovitzky, D.; 
Urízar, L., 1997). To amplify these results we assessed in vitro the synthesis of the cytokines - 
transforming growth factor beta (TGF-) and IL-1. Reduced concentrations of IFN- and IL-
4 and an increased synthesis of TGF- were observed in patients with moderate tuberculosis 
in comparison with those with mild disease.  
In patients with severe disease, PBMC synthesize the highest levels of IL-4 and TGF-, with 
low levels of IFN- synthesis, suggesting that in these cases an expressed Th2-type response 
suppresses the Th1 reaction in vitro (Dlugovitzky, D.; Bay, M. L.; Rateni, L.; Urízar, L.; 
Rondelli, C. F.; Largacha, C.; Farroni, M. A.; Molteni, O. & Bottasso, O. A., 1999). 
Rook et al confirmed this type of response and demonstrated strong links between IL-4 
and TGF-. In their studies PBMC from patients with the most advanced TB showed the 
highest release of both IL-4 and TGF- (Rook, G. A. W.; Lowrie, D. B. & Hernandez-
Pando, R., 2007; Hernández-Pando, R.; Aguilar, D.; Orozco, H.; Cortez, Y.; Brunet, L. R. & 
Rook, G. A., 2008).  
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The immune system generally responds in a regulated way to microbes and eliminates 
them, but it does not respond to self-antigens unless regulatory mechanisms are impaired 
and unresponsiveness or tolerance to self-antigens is not maintained (Van Parijs, L. & 
Abbas, A. K., 1998). Such a disharmonic immune response may result in several 
autoimmune diseases. The altered Th1 and Th2 expression found in severe tuberculosis 
patients may lay them open to such diseases. To investigate this we inquired into the 
incidence of arthritic manifestations (Poncet’s disease) in such patients. The kinds and 
distribution of T cell subsets in these cases and the presence of several auto-antibodies were 
also investigated. In the detected arthritic cases an augmented number of CD4+ Tcells was 
observed in comparison with CD8+ T cells and autoantibodies were detected. However, we 
could not rule out the presence of unknown factors that might be partly responsible for the 
reactive arthritis. (Dlugovitzky, D.; Torres, A.; Hourquescos, M. C.; Svetaz, M. J.; Quagliato, 
N.; Valentini, E.; Amigot, B.; Molteni, O. & Bottasso, O., 1995; Kroot, E. J.; Hazes, J. M.; Colin, 
E. M. & Dolhain, R. J., 2006) 
In addition to these results it has been demonstrated that CD8+ cells also synthesize IL-4, 
and this cytokine profile correlates with cavitation (van Crevel, R.; Karyadi, E.; Preyers, F.; 
Leenders, M.; Kullberg, B. J.; Nelwan, R. H. & van der Meer, J. W., 2000). 
Several studies have established that continuous IL-12 production is necessary for 
maintenance of the pulmonary Th1 cells required for host control of persistent Mtb infection 
and suggest that breakdown of this mechanism could be a contributing factor in the 
reactivation of disease (Feng, C. G.; Jankovic, D.; Kullberg, M.; Cheever, A.; Scanga, C. A.; 
Hieny, S.; Caspar, P.; Yap, G. S. & Sher, A., 2005). 
The capacity of IL-12 to induce the differentiation of naive CD4+ T cells into Th1 cells and 
stimulate production of IFN- was investigated by studying the capacity of PBMNC from 
patients with different severities of tuberculosis to produce IFN-, IL-4 and IL-12. The 
production of IFN- is increased in patients with less severe tuberculosis rather than in those 
with severe disease (Dlugovitzky, D.; Bay, M. L.; Rateni, L.; Fiorenza, G.; Vietti, L.; Farroni, 
M. A. & Bottasso, O. A., 2000). In this study we also demonstrated that Tumour Necrosis 
Factor-alpha (TNF-) production is increased in moderate and advanced tuberculosis 
patients and nitrite levels are augmented in severe tuberculosis cases, significantly different 
from those of healthy controls (Feng, C. G.; Jankovic, D.; Kullberg, M.; Cheever, A.; Scanga, 
C. A.; Hieny, S.; Caspar, P.; Yap, G. S. & Sher, A., 2005; Trinchieri, G., 2003; Casanova, J. L. & 
Abel, L., 2002; Fieschi, C. & Casanova, J. L., 2003). Several mycobactericidal and 
immunoregulatory mechanisms are developed by host cells including the production of NO 
and inflammatory cytokines, through extra- and intra-cellular mediated cytotoxicity, or 
cytostatic activity, which restrain a variety of pathogens including Mtb (Vouldoukis, I.; 
Riveros-Moreno, V.; Dugas, B.; Ouaaz, F.; Bécherel, P.; Debré, P.; Moncada, S. & Mossalayi, 
M. D., 1995; Kitabatake, A; Sakuma, I., 1999). 
Our results suggest that the synthesis of nitric oxide by the host is not always associated 
with a favourable evolution since higher levels are synthesized in cases with severe 
tuberculosis. Other authors propose that this event may be related to the interaction of 
several cytokines and/or eicosanoids through disease related induction of immune 
reactions (Tunçtan, B.; Okur, H.; Calişir, C. H.; Abacioğlu, H.; Cakici, I.; Kanzik, I. & 
Abacioğlu, N., 1998). It has also been shown that an inverse correlation exists between TNF-
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, TGF- and NO concentrations in serum, behavior that could be a predominantly TGF- 
effect (Fiorenza, G.; Rateni, L.; Farroni, M A.; Bogué, C. & Dlugovitzky, D. G., 2005). 
The production of NO, TNF- and IL-12 by the peripheral blood monocytes of patients 
suffering from MDR-TB has been investigated by others and NO production was found to be 
significantly depressed. A sub-cellular fraction of Mtb whole cell lysate, culture filtrate protein 
or lipoarabinomannan induced higher concentrations of NO to be released by peripheral 
blood monocytes from newly diagnosed tuberculosis patients in comparison with those from 
MDR-TB patients (Sharma, S.; Sharma, M.; Roy, S.; Kumar, P. & Bose, M., 2004).  
Respiratory diseases treated with M. vaccae to date have been: Pulmonary tuberculosis, 
Bronchial aspects of hay-fever, Bronchial asthma, Lung cancer 
Related conditions under investigation Chronic obstructive pulmonary disease (COPD) in 
man and recurrent airway obstruction (RAO) in horses. 
Arterial disease. 
Myocarditis. 
(These are being investigated with related bacterial immuno-modulators) 
4. Salient results of immunotherapy studies in treatment of tuberculosis 
In a preliminary study conducted some years ago in Carrasco Hospital, 14 pulmonary 
tuberculosis patients receiving heat-killed, borate-buffered M. vaccae (SRL172) had a better 
outcome than did 7 patients who received placebo (Vacirca, A.; Dominino, J. C.; Valentín, E; 
Bottasso, O. & Stanford, J., 1993. Subsequently we have carried out three small studies of 
this immunotherapy. All were performed in newly diagnosed, moderate to severe, 
pulmonary tuberculosis patients. In the first of these, the effects of a single dose given by 
intradermal injection was monitored to evaluate the potential of the approach and assess the 
value of the selected investigations. Levels of IFN- rose and TNF- fell, with decreases also 
in levels of IL-4, IL-10 and anti-hsp 70 kDa (Dlugovitzky, D.; Bottasso, O.; Dominino, J. C.; 
Valentini, E.; Hartopp, R.; Singh, M.; Stanford, C. & Stanford, J., 1999) (Table 1). From 
subsequent researches performed by our group, we concluded that immunotherapy with M. 
vaccae promotes changes in the immune response and improves patient recovery. 
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Fig. 1. Plasma levels of interleukin-4 for patients treated with placebo, intradermal or oral 
Mycobacterium vaccae. id: Intradermal, o: oral. 
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 Immunotherapy  Placebo Controls 
Hsp 65 kD n=13  n=11 n=12 
On admission 0.30±0.03  0.23±0.04 0.20±0.04a 
 P<0.001  P<0.05  
After 1 month 0.19±0.02  0.2±0.02  
% decrease 32±5.5 P<0.05 15.6±5.4  
Hsp 70 kD     
On admission 0.59±0.05  0.62±0.06 0.25±0.06b 
 P<0.001  n.s.  
After 1 month 0.31±0.03 P<0.001 0.53±0.06  
% decrease 48±3.6 P<0.0001 17±2.6  
IL-4     
On admission 685±77  586±63 69±9b 
After 1 month 342±36 P<0.02 495±58  
% decrease 47±4.7 P<0.001 15±4.9  
IL-10     
On admission 3800±302  3863±270 35±6b 
After 1 month 2292±187 P<0.002 3663±286  
% decrease 38±5.3 P<0.007 16.5±5.8  
IFN-     
On admission 524±76  553±57 157±7b 
After 1 month 1172±173 P<0.05 700±99  
% increase 124±21 P<0.005 41±20  
TNF-     
On admission 86±6  85.5±3.3 None detectableb 
After 1 month 52±5 P<0.001 74±3.7  
% decrease 38±3.6 P<0.01 14±4.1  
a Different form immunotherapy group. P<0.02 
b Different from immunotherapy and placebo groups. P<0.001 n.s., not significant 
Table 1. Result of ELISA absorption measurements. ± SE of IgG antibodies to heat shock 
proteins 65 kD and 70 kD and of the serum cytokines interlukin-4 (IL-4), interleukin-10 (IL-
10), interferon gamma (IFN-) and tumor necrosis factor alpha (TNF-) in pg/ml 
Salient results of serology and cell culture supernatant immunology of data drawn from all 
three studies of M. vaccae, injected or oral are shown. With the rise in serum IFN-and fall in 
serum IL-4 (Fig. 1), is seen a reduction in production of IgG antibodies to stress proteins and 
a reduction in circulating TNF- (Fig. 2). Culture supernatants of both PBMC and PMN cells 
showed steady increases with time of IFN- and IL-2, and as the disease regressed 
production of TNF- fell steeply. 
In addition to these results it has been demonstrated that CD8+ cells also synthesize IL-4, 
and this cytokine profile correlates with cavitation (van Crevel, R.; Karyadi, E.; Preyers, F.; 
Leenders, M.; Kullberg, B. J.; Nelwan, R. H. & van der Meer, J. W., 2000). 
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TNF  levels in plasma
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Fig. 2. Plasma TNF- values for patients treated with placebo, intradermal or oral 
Mycobacterium vaccae. id: Intradermal, o: oral. 
Respiratory Burst expression (Fig. 3) increased in the successives samples of intradermal 
and oral M. vaccae treated TBP, and it was higher in those patients receiving oral M. vaccae 
then in those receiving intradermal Mv in relation to placebo recipients.  
IFN-(Fig. 4), TNF-(Fig. 5), IL-6 and IL-10 (Fig. 6) levels in PBMC and PMN culture 
supernatants. and IL-6, IL-10 (Fig. 7) and TNF- values in plasma (Fig. 2) also increased 
more in those receiving oral M. vaccae than in intradermal M. vaccae recipients.The 
immunomodulatory effect of both oral M. vaccae and intradermal. M. vaccae treatments was 
shown both by Respiratory Burst expression and cytokine increase in culture supernatants 
and plasma, with oral therapy the more effective. 
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Fig. 3. Respiratory index for polymorphonuclear cells and for mononuclear cells, calculated 
by dividing the mean fluorescence value for H37Rv-stimulated cells by the mean 
fluorescence value for unstimulated cells. 
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Fig. 4. IFN-levels in the supernatants of cultured cells 
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TNF-  levels in the supernatants of  PBMNC
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Fig. 5. TNF- levels in the supernatants of cultured cells 
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IL-10 levels in the supernatants of  PMN
(unstimulated culture)
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Fig. 6. IL-10 levels in the supernatants of cultured cells.  
The data obtained with all 3 immunotherapy regimens produced significantly better results 
than those achieved with chemotherapy alone.  
The data show that the addition of oral capsules of M. vaccae to a DOTS program in the 
treatment of drug-sensitive tuberculosis would have the clinical advantages of hastening 
sputum negativity and recovery from the disease. Such a strategy would reduce new 
infections, both among contacts and in the community at large and might allow shortening 
of the treatment period.  
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Fig. 7. Plasma IL-10 values for patients treated with placebo, intradermal or oral 
Mycobacterium vaccae. id: Intradermal, o: oral. 
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The mechanism of action of injected M. vaccae is thought to be via immunomodulating adju-
vant activities of the mycobacterial cell envelope. The short amino acid-chain lengths of 
common mycobacterial antigens and sugars preserved by the borate buffer on dermal 
dendritic cells (Stanford, J. L. & Grange, J. M., 1974; Stanford, J.; Stanford, C.; Stansby, G.; 
Bottasso, O.; Bahr, G. & Grange, J., 2009; Hernández-Pando, R.; Aguilar, D.; Orozco, H.; 
Cortez, Y.; Brunet, L. R. & Rook, G. A., 2008) act to direct the modulated response to the sites 
of expression of host-cell stress proteins (Matzinger, P., 1994). This may be especially to 
those stress proteins of mitochondrial origin showing homologies with the common 
antigens of mycobacteria (Cohen, I. R. & Young, D. B., 1991) and the bacteriomimetic sugars 
expressed by rapidly replicating cells. The results reported in animals (Stainsby, K. J., 1989; 
Zuany-Amorim, C.; Sawicka, E.; Manlius, C.; Le Moine, A.; Brunet, L. R.; Kemeny, D. M.; 
Bowen, G.; Rook, G. & Walker, C., 2002; Hernandez-Pando, R.; Pavon, L.; Arriaga, K.; 
Orozco, H.; Madrid-Marina, V. & Rook, G., 1997) and our observations in man suggest that 
the same, or similar, beneficial immunomodulation can be stimulated via the mucosal 
immune system, where the multifold (M) cells (Gebert, A.; Rothkotter, H. J. & Pabst, R., 
1996) of the intestine play a part analogous to that of the dermal dendritic cells in the skin.  
In addition to the reported immunological results, the bacteriological findings indicated that 
the conversion to negative of both sputum smear and culture was significantly enhanced by 
injected or oral immunotherapy with M. vaccae above that achieved by chemotherapyalone.  
Although this study deals with drug-sensitive tuberculosis, the reported immunological 
changes, which are paralleled in both injected and oral studies, allow confidence that the 
oral formulation will prove of similar efficacy in patients infected with drug-resistant 
bacilli (Stanford, J. L.; Stanford, C. A.; Grange, J. M.; Lan, N. N. & Etemadi, A., 2001). This 
would accord with our earlier experience of intradermal injection of M. vaccae in patients 
with a variety of drug resistance (Farid, R.; Etemadi, A.; Mehvar, M.; Stanford, J. L.; 
Dowlati, Y. & Velayati, A. A., 1994; Corlan, E.; Marica, C.; Macavei, C.; Stanford, J. L. & 
Stanford, C. A., 1997) in many countries (Stanford, J. L.; Stanford, C. A.; Grange, J. M.; 
Lan, N. N. & Etemadi, A., 2001), where excellent clinical results have already been 
obtained in the treatment of MDR-TB. As the immunological data obtained in the oral 
study, albeit with a more intensive schedule, paralleled that of the intradermal study it is 
logical to suppose that MDR-TB could also be treated successfully with oral M. vaccae. The 
properly functioning immune system recognizes and regulates the appropriate response 
to disease and would be capable of destroying both drug-sensitive and drug-resistant 
organisms quite impartially.  
This approach to treatment at the outset would allow initial resistance to be treated early 
and at the same time discourage secondary resistance due to treatment inadequacy. As an 
example, at the chest hospital in Ho Chi Minh City, Vietnam, 12 patients accepted for 
immigration into the USA were subsequently found to be infected with highly drug-
resistant organisms. They failed to be cured with the latest drugs provided from the USA, 
but following up to twelve injections of M. vaccae (administered on the initiative of the staff 
of the Chest Hospital) all were cured and allowed into the USA. Similar results have been 
obtained in several countries (Stanford, J. L.; Stanford, C. A.; Grange, J. M.; Lan, N. N. & 
Etemadi, A., 2001).  
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5. Conclusions of the 3 studies 
The inclusion of immunotherapy with SRL-172 improved the results of DOTS chemotherapy 
and it led us to the conclusion that this therapy might allow a reduced period of 
chemotherapy without loss of efficacy and help to prevent the development of multi-drug-
resistance. The three small studies of immunotherapy with heat-killed, borate-buffered, M. 
vaccae for drug-susceptible pulmonary TB developed in the department in Medicine Faculty 
of Rosario have produced successful results. It was demonstrated that the transformation of 
a Th2 response, towards Th1, is accompanied by clinical, bacteriological and radiological 
improvement in the immunotherapy recipients. 
The results showed that three injected doses of M. vaccae were more effective than a single 
dose, and that ten oral doses scattered throughout the period of chemotherapy, were as 
effective, or more so, than was the injected preparation. The reagent deserves formal field 
trials, particularly in patients infected with highly drug-resistant strains of tubercle bacilli. 
In conclusion, we have found that immunotherapy with M. vaccae in TB, whether by 
injection or by the oral route, hastens recovery, bacteriologically, clinically and 
radiologically, as well as returning immune responses towards those of healthy persons.  
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